Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
:( i hope it.
tell your friends buy DEAR! lol
POWER HOUR common pump that DOW!
very very low volume on this down day. expecting soemthing bigger next week. if market is pointing to the right direction. your 3s is next stop.
holding good here on low volume so far.
i belive because its a almost broke pharma stock and only significant news about their drug can move this. but it closed higher today so..its up aswell.
this will go to the MOON if the DOW can break thru 200 Day MA at 10300!
looking great here still plenty room to move. if market keeps going ill take your 3s.
Bid Price 3.20 USD Ask Price 3.47 USD AH
took prrofit of the table, were at 20 day MA resistance. will buy back in .
in 2,11 out 2.54$
cool.
didnt expect such a huge move at all!! yees HAMMER TIME!
i got this in my mail about 15 min ago.
POZEN Announces Receipt of $20 Million Milestone Payment from AstraZeneca
Back into DEAR! let the Ask goo.
0.77$ close?
patience paid off i guess?
The Roots - How I Got Over
i agree. nice EOD buying and were closing 4c above the 200 Day SMA. SNSS still in play IMO. June 7th is Keydate here, thats what the chart is saying aswell.
intraday breakdowns doesnt counts. if we can close and stay above the 200 Day today and in the coming days, nothing is lost IMO. i dunno why they do it, maybe they need money for Phase 3 and they do it before ASCO and before the News that Phase 3 is going to be launched. but that would all be speculation from my side here. arround june 7th and after will be Key Date here IMO. hope the market can absorbe all the shares.
bought here a position of AEZS 1.72$ going into June.
best of luck
how comes that JAV stock doesnt care at all about the open gap in between 1.40$ and 2.10$?
Javelin Pharmaceuticals Inc.' Receives FDA PDUFA Date For Dyloject NDA
Wednesday, 17 Feb 2010 08:55am EST
Javelin Pharmaceuticals Inc. announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject (diclofenac sodium) Injection, has received an FDA PDUFA date of October 3, 2010. This NDA review is in support of US marketing approval and registration of Dyloject for the management of acute moderate-to-severe pain in adults. If approved, Dyloject will be the first IV non-steroidal anti-inflammatory drug (NSAID) marketed in the United States as a single agent for the management of acute moderate-to-severe pain in adults since ketorolac in 1990. Javelin`s NDA includes 16 clinical studies evaluating over 2000 subjects dosed with Dyloject. It includes over 1300 US patients in two multi-dose, multiple-day placebo-controlled Phase 3 pivotal efficacy studies and one multi-dose, multiple-day open label safety study.
http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=JAV×tamp=20100412132500
Hospira, Inc. And Javelin Pharmaceuticals Inc. Enter Into Definitive Merger Agreement For Hospira To Acquire Javelin Pharmaceuticals; Hospira Will Initiate Tender Offer
Monday, 19 Apr 2010 09:16am EDT
Hospira, Inc. and Javelin Pharmaceuticals, Inc. announced that the companies have entered into a definitive merger agreement providing for the acquisition of Javelin by Hospira for $2.20 per share in cash, or approximately $145 million. Hospira expects to commence a tender offer for all outstanding shares of Javelin common stock on or about April 21, 2010, in accordance with the terms of the merger agreement. Hospira entered into the merger agreement following an extensive evaluation of Javelin's business and its prospects. The offer is conditioned on the tender of a majority of Javelin's shares calculated on a fully diluted basis. Hospira and Javelin also entered into a loan facility under which Javelin may borrow up to $4.5 million to fund Javelin's operating activities prior to closing a merger with Hospira, approximately $8.3 million for Javelin's repayment of the principal and accrued interest incurred under a similar financing arrangement entered into with Myriad Pharmaceuticals (MPI) and $4.4 million for Javelin's payment of the termination fee and certain stipulated expenses that Javelin may be required to pay MPI following termination of its merger agreement with MPI.
http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=JAV×tamp=20100419131600
Kendall Law Group Investigating Javelin Pharmaceuticals Inc. Merger Agreement
Monday, 19 Apr 2010 05:20pm EDT
Kendall Law Group announced that it is investigating the merger of Javelin Pharmaceuticals, Inc. with Hospira, Inc. on behalf of Javelin shareholders. The national securities litigation firm is investigating whether a fair process was used by Javelin`s Board of Directors prior to entering into the merger agreement and whether they breached their fiduciary duties by not seeking a deal that would provide better value of the Company for shareholders.
http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=JAV×tamp=20100419131600
Javelin Pharmaceuticals, Inc. Reports First Quarter 2010 Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV - News), a leading developer of novel acute care pain products, today reported its unaudited financial results for the first quarter ended March 31, 2010.
“Management's Discussion and Analysis of Financial Condition and Results of Operations”
Highlights for the three months ended March 31, 2010:
Ended the first quarter with approximately $1.1 million in cash and cash equivalents
Net loss decreased to approximately $6.3 million, or $0.10 per share, in the first quarter of 2010 from approximately $14.8 million, or $0.24 per share, in the first quarter of 2009
In February 2010, Javelin received an FDA PDUFA date of October 3, 2010 for Dyloject™
On April 19, 2010, Javelin announced that it had entered into a Definitive Merger Agreement with Hospira, Inc. pursuant to which Hospira launched an all cash tender offer of $2.20 per share. The transaction is scheduled to close during the second quarter of 2010.
Financial Performance
For the three months ended March 31, 2010, we recorded $0.3 million in amortization of partner milestone payments compared to $0.2 million for the similar period a year ago. For the three months ended March 31, 2009, partner revenue also included approximately $1.7 million in product sale to Therabel.
For the three months ended March 31, 2010, our cost of revenue was approximately $0.1 million, compared to $1.9 million for the same period a year ago. Our cost of revenue for the period ended March 31, 2010 is primarily attributable to our portion of royalties that were payable to third parties for sales recorded by Therabel.
Research and development expenses for the three months ended March 31, 2010, were $3.9 million compared to $11.8 million for the same period in 2009. Total research and development expense for the quarter decreased to $6.5 million from $16.9 million for the similar period a year ago, primarily attributable to reductions in clinical trial expenses for Dyloject and Ereska.
Selling, general and administrative expenses for the three months ended March 31, 2010 were $2.5 million, compared to $3.0 million for the first quarter of 2009. The reduction was primarily the result of decreased sales and marketing expense, a reduction in compensation and benefits from reduced stock option compensation and overall cost savings initiatives across the Company.
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20100510006985&newsLang=en
L.T.D - LOVE BALLAD (1976)
Ruyan Group (Holdings) Limited Announces Proposed Placing Of New Convertible Bonds
Reuters Key Development - May 6, 2010
http://www.google.com/finance/company_news?q=HKG:0329&newsbefore=2010-05-07
The most important Video youll ever seen.
back on PFBC Track.
Back Today into DEAR 2.20$. not much Volume arround and looking for a green Monday!
glta
RPC 1.40$
RPC 1.38$
RPC 1.38$
RPC Pre Market Low 1.39$ High 1.60$
good looks traders!
Radient Pharmaceuticals Accelerating Distributor Partnerships for Its Onko-Sure In Vitro Diagnostic Cancer Test in India via Government and Distributor Meetings
TUSTIN, CA, May 14, 2010 (MARKETWIRE via COMTEX) -- Through its US-based subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation (RPC) /quotes/comstock/14*!rpc/quotes/nls/rpc (RPC 1.50, -0.14, -8.54%) announced today its executive management will be in India May 20, 2010 through May 25, 2010 with the goal of accelerating the commercialization of RPC's Onko-Sure(TM) in vitro diagnostic (IVD) cancer test in India through distribution partnerships with Gaur Diagno (New Delhi).
More specifically, RPC's executive management team will be solidifying expanded partnership agreements for the sales and marketing of Onko-Sure test kits with Gaur Diagno; and the development of clinical trials for RPC's Combination Immunogene Therapy (CIT) technology with Jaiva Technologies.
According to Mr. Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals, "Measurable progress for Onko-Sure cancer testing is of the utmost importance for Radient Pharmaceuticals and its employees, customers, partners and shareholders. We have scheduled meetings with a highly anticipated program launch with key government officials in India in support of the commercialization of our US FDA approved Onko-Sure IVD cancer test. Through discussions, we anticipate receiving Indian government support in various regions to implement Onko-Sure as a general cancer screening tool in India -- one of the first major initiatives for Onko-Sure as a cancer testing/screening tool. India is top tier market for RPC's Onko-Sure IVD cancer test."
http://www.marketwatch.com/story/radient-pharmaceuticals-accelerating-distributor-partnerships-for-its-onko-sure-in-vitro-diagnostic-cancer-test-in-india-via-government-and-distributor-meetings-2010-05-14?reflink=MW_news_stmp
Radient Pharmaceuticals Corporation (RPC) (AMEX:RPC) surged 67% today after a positive research report was issued by Goldman Research. Said analyst Rob Goldman, "We view Radient as a stock that offers great value and potential for its existing operations, hidden but soon-to-be monetized value in its non-core assets, and home run potential with its next-gen product, should it be awarded FDA approval. A steady stream of news and events prior to FDA submission should serve as catalysts for the stock." Goldman rated Radient a speculative buy with a $4.00 price target.
http://biomedreports.com/articles/most-popular/40298-rxnews-recap-for-thursday-05-13-10.html
got in and out 3 Times today :D